ARS Pharmaceuticals (SPRY) Cash from Financing Activities (2020 - 2026)

ARS Pharmaceuticals has disclosed Cash from Financing Activities across 7 years of filings, most recently posting $159000.0 for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $159000.0, down 78.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $104.0 million (up 42.77% YoY), and the FY2025 annual result was $104.6 million, up 44.47% from the prior year.
• Cash from Financing Activities came in at $159000.0 for Q1 2026 at ARS Pharmaceuticals, down from $1.1 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $193.8 million in Q4 2022 to a low of -$1.6 million in Q3 2022.
• The 5-year median for Cash from Financing Activities is $921000.0 (2023), against an average of $22.0 million.
• Across the five-year window, Cash from Financing Activities sank 1151.35% in 2022 and soared 14612.5% in 2025, its largest moves.
• ARS Pharmaceuticals' Cash from Financing Activities stood at $193.8 million in 2022, then plunged by 99.07% to $1.8 million in 2023, then jumped by 3828.86% to $70.9 million in 2024, then slumped by 98.41% to $1.1 million in 2025, then slumped by 85.94% to $159000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $159000.0 (Q1 2026), $1.1 million (Q4 2025), and $100.0 million (Q3 2025), per Business Quant data.